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Theprevalenceofhypertensionincreaseswithadvancingage.Themanagementofhypertensionespeciallyintheelderlyhasitsown
limitations. Verapamil is not recommended in the elderly on account of high incidences of troublesome constipation. Amlodipine
has become very popular with the cardiologists and general physicians. Survey of literature has not yielded any citation where
the troublesome eﬀect of amlodipine on the gastrointestinal tract has been reported. In an experimental study on isolated rabbit
intestinewehavedemonstratedthatamlodipinedose-dependentlyinhibitthespontaneousactivityoftheintestinaltract.Withthis
background the present observational study was planned. A total of 100 hypertensive patients were included in the present study.
Fiftypatientswereonamlodipinealoneand50patientsoncombinationofamlodipineandatenolol.Themainparameteranalyzed
was the frequency and consistency of stool before and after intake of drug. The relative risk (RR) of developing constipation
was 4.00 with 95% CI 0.8930 to 17.917 in amlodipine alone group. From this study it can be concluded that the relative risk of
developing constipation is 4 times more in patients who are taking amlodipine alone as compared to those patients who are on
combination of amlodipine and atenolol.
1.Introduction
The prevalence of hypertension increases with advancing
age; for example, about 50% of people between the ages of
60 and 69 years old have hypertension, and the prevalence
is further increased beyond age 70 [1]. The management
of hypertension especially in the elderly has its own lim-
itations. Drugs used in hypertension are calcium channel
blockers (CCBs), angiotensin converting enzyme inhibitors
(ACEIs), and low-dose diuretics [2]. Verapamil, belonging
to papaverine group, is not recommended in the elderly
on account of high incidences of troublesome constipation
[2]. Amlodipine, pharmacokinetically the most distinct type
of dihydropyridine (DHP) CCB, has become very popular
with the cardiologists and general physicians in doses of
5mg or 10mg once daily [3, 4]. Survey of the literature
has not yielded any citation where the troublesome eﬀect
of amlodipine on the gastrointestinal tract (GIT) has been
reported [5]. We had demonstrated in an experimental study
on isolated rabbit intestine that amlodipine dose depen-
dently inhibits the spontaneous activity of the intestinal tract
[6]. With this background the present observational study
was planned to demonstrate the experimental observation in
the hypertensive patients’ population coming to the medical
OPD in our hospital. Therefore, the aim of the present study
was to demonstrate the eﬀect of amlodipine alone and in
combination with atenolol on the bowel habits in patients
who are taking these drugs.
2.MaterialsandMethods
This was a noninterventional observational study. The
present study was approved by local institutional ethics
committee. The subject of the present study was the patient2 ISRN Gastroenterology
population attending the hypertensive clinic in our institu-
tion. Both male and female patients with age 40–70 years,
taking amlodipine alone or in combination with atenolol,
were screened for this present study. Patients with history of
intake of any other medicines or history of any other diseases
that can decrease intestinal motility like hypothyroidism
were excluded from the study. Written informed consent was
taken from the patients before being included in the study.
A questionnaire-based proforma was ﬁlled for each patient
which includes the frequency and consistency of the stool
before and after the drug intake, presence of blood in stool
and hard stool, the duration of drug intake, the dose of the
drug, the use of laxatives, physical activity, and diet, and
was ﬁlled for each patient. The answers were then compiled,
tabulated, and analyzed. The constipation was deﬁned as the
history of less than 3 spontaneous bowel movements (SBM)
per week for a period of at least 6 months [7].
3.StatisticalAnalysis
T h ed a t aa r ee x p r e s s e da sm e a n± SD and as absolute
number of patients whenever applicable. The relative risk of
developing constipation and blood in stool and hard stool
was calculated in both the patient groups who are taking
amlodipine alone or in combination with atenolol by using
Fisher’s exact test. The other variables like age, sex, SBM/wk,
and duration of treatment were compared by using unpaired
“t” test. P<. 05 was considered statistically signiﬁcant.
4. Results
A total of 100 patients who attended the hypertensive clinic
in Government Medical College and Hospital, Chandigarh,
were included in the study after the screening. Fifty patients
were on amlodipine alone and 50 patients were on combina-
tion of amlodipine and atenolol.
Table 1 depicted the data of all 100 patients. There was
no signiﬁcant diﬀerence in the baseline characteristics in
both the groups. The baseline SBM/wk was comparable
(8.64 ± 4.4v e r s u s7 .84 ± 2.5) in both the groups (Table 1).
The number of patients in the amlodipine group with
SBM/wk less than 3 was 8 whereas in combination group
(amlodipine + atenolol) it was 2 (P = .045, Fisher’s
exact test, signiﬁcant). The relative risk (RR) of developing
constipation was 4.00 with 95% CI 0.8930 to 17.917 in
amlodipine alone group. However, there was no signiﬁcant
diﬀerence in SBM/wk in both the groups before and after
treatment (P>. 05). The majority of the patients in both
the groups were on amlodipine 10 mg daily dose (28(56%)
patients in amlodipine group and 29(58%) patients in
combination group) (Table 1). The duration of treatment
with amlodipine was also comparable in both the groups
(16.75 ± 2.5 months versus 14.025 ± 2.58 months). The
number of patients with blood in stool was 5 in amlodipine
group while there was none in the combination group (P =
.028,signiﬁcant).Straining/hardstoolwasseenin10patients
in the amlodipine group and 3 patients in the combination
group (P = .035, signiﬁcant) (Table 1). The risk (RR =
3.33 with 95% CI 0.9748 to11.399) of developing hard stool
Table 1: Eﬀects of amlodipine alone and in combination with
atenolol on bowel habit in patients with hypertension. SBM:
spontaneous bowel movement. Results are expressed as mean ±SD
and absolute number.
Parameters Amlodipine
(n = 50)
Amlodipine
+ atenolol
(n = 50)
Age (Yrs) (M ±SD) 54.14 ±11.32 54.36 ±10.27
Male:Female 23:27 21:29
SBM/wk (M ±SD)
Before treatment 8.64 ±4.47 .84 ±2.5
After treatment 8.0 ±4.77 .44 ±2.64
No of patients with SBM/wk < 38 ∗ 2
No. of patients with blood in stool 5∗∗ 0
No. of patients with straining/hard
stool 10
∗∗∗ 3
Duration of treatment (Months)
(M ±SD) 16.75 ±2.51 4 .025 ±2.6
Dose of amlodipine
No. of patients taking 5mg OD 22 21
No. of patients taking 10mg OD 28 29
No. of patients taking isabgual 5 4
∗P = .045, Fisher’s exact test, RR = 4.00.
∗∗P = .028, Fisher’s exact test.
∗∗∗P = .035, Fisher’s exact test, RR = 3.33.
was more in amlodipine group. The number of patients
taking laxatives was 5 in amlodipine alone group and 4 in
combination group (P>. 05).
5. Discussion
So from the present observation, it can be said that amlodip-
ine alone associated with increased incidence of constipation
(RR = 4.00) and hard stool (RR = 3.333) and when atenolol
was combined, the incidence of constipation and hard stool
was less (P<. 05). Like our previous animal study, this
observational study also demonstrated that amlodipine can
reduce the peristaltic activity of the intestine when used
alone. From this observation and previous animal study,
we can hypothesized that when amlodipine is used alone it
could reduce the peristaltic activity of the intestine which
may be due to the release of catecholamines (like nifedipine)
[5], and subsequent interaction of this catecholamines with
the adrenergic receptors present in the gastrointestinal tract
may lead to constipation. However, when amlodipine was
combined with atenolol, the released catecholamine was
unable to produce an eﬀect as β-adrenergic receptor in
the GIT was blocked by atenolol. The Indian populations,
especially the advancing age group, are very much concerned
about their bowel evacuation. Such hypertensive patients
who suﬀer constipation on account of the drug can also have
the mental stress which can further facilitate the release of
catecholamines and may have deleterious eﬀect on the bowel
habits. Hence, in an elderly patient having concomitantISRN Gastroenterology 3
compromisedGITandhypertensionwarrantsajudicioususe
of amlodipine. Further study is in progress.
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